P3.15-27 Initial Response to First Line Treatment Is the Best Predictor of the Patient Survival in Advanced NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1903
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Neoplasma
Cancer Research
2013English

P3.01-44 CYFRA 21-1 as a Predictor to Response to Chemotherapy and Overall Survival in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.15-27 Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Osimertinib as First-Line Therapy in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives
Pharmacology
2018English

Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2008English

Identification and Interpretation of Clinical and Quality of Life Prognostic Factors for Survival and Response to Treatment in First-Line Chemotherapy in Advanced Breast Cancer

European Journal of Cancer
Cancer ResearchOncology
2000English

P3.15-12 Survival Impact of Patient Enrollment in Antineoplastic Drug Trials for Stage IV Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy